News & Updates

HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART
HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART
04 Dec 2022

Among people living with HIV on active antiretroviral therapy (ART), coinfection with the hepatitis B (HBV) or hepatitis C (HCV) viruses does not seem to significantly worsen immunologic and virologic response to treatment, a recent study has found.

HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART
04 Dec 2022
Age, sex, syphilis risk factors for COVID-19 in PLHIV
Age, sex, syphilis risk factors for COVID-19 in PLHIV
30 Nov 2022 byRoshini Claire Anthony

Among people living with HIV (PLHIV), young women and patients with active syphilis appeared to be at an elevated risk of contracting COVID-19, according to a cross-sectional study presented at HIV Glasgow 2022.

Age, sex, syphilis risk factors for COVID-19 in PLHIV
30 Nov 2022
Breath-holding may predict adverse outcomes in COVID-19 patients
Breath-holding may predict adverse outcomes in COVID-19 patients
28 Nov 2022
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022

Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.

Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Which factors raise HCC risk in patients with cured HCV?
Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022 byStephen Padilla

Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.

Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022

A significant number of patients with infective endocarditis have been found to have antineutrophil cytoplasmic antibody (ANCA), which is associated with longer disease duration, more frequent purpura, and kidney involvement, results of a study has shown.

ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022

Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.

Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022